Griffin Securities Starts AmpliPhi Biosciences (APHB) at Buy

March 8, 2016 11:14 AM EST
Get Alerts APHB Hot Sheet
Price: $0.32 --0%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 22 | Down: 26 | New: 45
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Griffin Securities initiates coverage on AmpliPhi Biosciences (NYSE: APHB) with a Buy rating and a price target of $10.00.

Analyst Keith Markey commented, "Ampliphi Biosciences is paving the way to new antibacterial medicines. The clinical-stage company is employing naturally occurring bacteriophage, which are viruses that attack only bacteria, as therapeutic agents. Scientific studies attest to their effectiveness in the environment and as therapeutic agents. The ancient microbes pose no known threat to humans and have been approved for by regulators for use on foods. Also, phage-based medicines are sold over the counter in some parts of the world."

For an analyst ratings summary and ratings history on AmpliPhi Biosciences click here. For more ratings news on AmpliPhi Biosciences click here.

Shares of AmpliPhi Biosciences closed at $4.07 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage